Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arthritis
The benefit/risk ratio for anti-TNF-alpha agents has been favorable
December 28th, 2004
A recent report provided an overview of the benefits and risks of biological agents. According to the report from the United States, "Targeted tumor necrosis factor-alpha antagonists, first approved by the U.S. Federal Drug Administration in 1998, have had a significant impact on the treatment of patients with rheumatoid arthritis. In general, the benefit/risk ratio for these agents and the IL-1 receptor antagonist, anakinra, has been quite favorable. However infrequent adverse events can be serious and require continued pharmacovigilance." A.K. Imperato and colleagues of New York University continued, "Infections, particularly tuberculosis and less...
Source: Cancer Weekly (2004-12-28)
|
